PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33006028-3	2021	In this retrospective study, we evaluated the performance of [18F]-JK-PSMA-7 under ADT.	adt	83-86	proteasome 20S subunit alpha 7	Homo sapiens	70-76	
33006028-13	2021	CONCLUSION: [18F]-JK-PSMA-7 PET showed a high detection rate in patients with PSA levels >= 0.3 ng/ml under ADT.	adt	108-111	proteasome 20S subunit alpha 7	Homo sapiens	21-27	
33398412-10	2021	CONCLUSION: Applying PSMA-based imaging for therapy monitoring in patients with CRPC should be considered with caution since a reduction in [18F]JK-PSMA-7 PET uptake after successive ADT and chemotherapy may be related to downregulation of PSMA expression in dedifferentiated and rapidly proliferating tumour cells.	adt	183-186	proteasome 20S subunit alpha 7	Homo sapiens	148-154	
27843206-8	2016	CONCLUSION: After a careful comparison between the trials, we conclude that systemic docetaxel chemotherapy within 4 months of initiating ADT for metastatic, high-volume HSPC should be considered the standard of care for patients with good performance status.	adt	138-141	proteasome 20S subunit alpha 7	Homo sapiens	170-174